{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:18:51Z","timestamp":1785903531127,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen Global Services, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40271-021-00501-7","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T01:03:02Z","timestamp":1615251782000},"page":"613-623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-3713","authenticated-orcid":false,"given":"Jianming","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Duenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Collacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Trevor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Tervonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"issue":"5","key":"501_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97(5):416\u201329. https:\/\/doi.org\/10.1111\/ejh.12790.","journal-title":"Eur J Haematol"},{"issue":"9","key":"501_CR2","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","volume":"23","author":"R Baz","year":"2015","unstructured":"Baz R, Lin HM, Hui AM, Harvey RD, Colson K, Gallop K, et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015;23(9):2789\u201397. https:\/\/doi.org\/10.1007\/s00520-015-2644-6.","journal-title":"Support Care Cancer"},{"issue":"1","key":"501_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","volume":"19","author":"JA Parsons","year":"2019","unstructured":"Parsons JA, Greenspan NR, Baker NA, McKillop C, Hicks LK, Chan O. Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC Cancer. 2019;19(1):264. https:\/\/doi.org\/10.1186\/s12885-019-5467-x.","journal-title":"BMC Cancer."},{"issue":"6","key":"501_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","volume":"12","author":"S Seitzler","year":"2019","unstructured":"Seitzler S, Finley-Oliver E, Simonelli C, Baz R. Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol. 2019;12(6):419\u201324. https:\/\/doi.org\/10.1080\/17474086.2019.1613886.","journal-title":"Expert Rev Hematol."},{"issue":"6","key":"501_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.12012","volume":"89","author":"TR Osborne","year":"2012","unstructured":"Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol. 2012;89(6):437\u201357. https:\/\/doi.org\/10.1111\/ejh.12012.","journal-title":"Eur J Haematol"},{"issue":"3","key":"501_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/bjh.14058","volume":"174","author":"D Robinson Jr","year":"2016","unstructured":"Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. Br J Haematol. 2016;174(3):368\u201381. https:\/\/doi.org\/10.1111\/bjh.14058.","journal-title":"Br J Haematol"},{"issue":"5","key":"501_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.15248","volume":"181","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, et al. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after\u2009\u22652 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. Br J Haematol. 2018;181(5):628\u201336. https:\/\/doi.org\/10.1111\/bjh.15248.","journal-title":"Br J Haematol"},{"key":"501_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1747066","author":"K Weisel","year":"2020","unstructured":"Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate AS, et al. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leuk Lymphoma. 2020. https:\/\/doi.org\/10.1080\/10428194.2020.1747066","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"501_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","volume":"105","author":"LK Nielsen","year":"2020","unstructured":"Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica. 2020;105(6):1650\u20139. https:\/\/doi.org\/10.3324\/haematol.2019.222299.","journal-title":"Haematologica"},{"issue":"1","key":"501_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","volume":"23","author":"D Postmus","year":"2018","unstructured":"Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, et al. Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018;23(1):44\u201351. https:\/\/doi.org\/10.1634\/theoncologist.2017-0257.","journal-title":"Oncologist."},{"issue":"4","key":"501_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, et al. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10\u00a0yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol. 2012;89(4):311\u20139. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01831.x.","journal-title":"Eur J Haematol"},{"issue":"3","key":"501_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","volume":"72","author":"N Gulbrandsen","year":"2004","unstructured":"Gulbrandsen N, Hjermstad MJ, Wisloff F, Nordic Myeloma Study Group. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol. 2004;72(3):172\u201380. https:\/\/doi.org\/10.1046\/j.0902-4441.2003.00195.x.","journal-title":"Eur J Haematol."},{"issue":"1","key":"501_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","volume":"15","author":"AC Sherman","year":"2009","unstructured":"Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transpl. 2009;15(1):12\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2008.09.023.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"501_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s41669-019-00184-9","volume":"4","author":"RM Rifkin","year":"2020","unstructured":"Rifkin RM, Bell JA, DasMahapatra P, Hoole M, Lowe M, Curran C, et al. Treatment satisfaction and burden of illness in patients with newly diagnosed multiple myeloma. Pharmacoecon Open. 2020;4(3):473\u201383. https:\/\/doi.org\/10.1007\/s41669-019-00184-9.","journal-title":"Pharmacoecon Open."},{"issue":"5","key":"501_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cpt.332","volume":"99","author":"D Postmus","year":"2016","unstructured":"Postmus D, Mavris M, Hillege HL, Salmonson T, Ryll B, Plate A, et al. Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators. Clin Pharmacol Ther. 2016;99(5):548\u201354. https:\/\/doi.org\/10.1002\/cpt.332.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"501_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","volume":"10","author":"EW de Bekker-Grob","year":"2017","unstructured":"de Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, et al. Giving patients\u2019 preferences a voice in medical treatment life cycle: the PREFER public-private project. Patient. 2017;10(3):263\u20136. https:\/\/doi.org\/10.1007\/s40271-017-0222-3.","journal-title":"Patient."},{"issue":"6","key":"501_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2016.04.008","volume":"19","author":"FR Johnson","year":"2016","unstructured":"Johnson FR, Zhou M. Patient preferences in regulatory benefit-risk assessments: a US perspective. Value Health. 2016;19(6):741\u20135. https:\/\/doi.org\/10.1016\/j.jval.2016.04.008.","journal-title":"Value Health."},{"issue":"2","key":"501_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-016-0763-8","volume":"18","author":"AC Muhlbacher","year":"2017","unstructured":"Muhlbacher AC, Bridges JF, Bethge S, Dintsios CM, Schwalm A, Gerber-Grote A, et al. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment. Eur J Health Econ. 2017;18(2):155\u201365. https:\/\/doi.org\/10.1007\/s10198-016-0763-8.","journal-title":"Eur J Health Econ."},{"issue":"10","key":"501_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229\u201345. https:\/\/doi.org\/10.1080\/08870440903194015.","journal-title":"Psychol Health."},{"issue":"1","key":"501_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","volume":"13","author":"IL Hollin","year":"2020","unstructured":"Hollin IL, Craig BM, Coast J, Beusterien K, Vass C, DiSantostefano R, et al. Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers. Patient. 2020;13(1):121\u201336. https:\/\/doi.org\/10.1007\/s40271-019-00401-x.","journal-title":"Patient."},{"key":"501_CR21","unstructured":"Friese S. ATLAS.ti 7 User Guide and Reference."},{"key":"501_CR22","unstructured":"Friese S, Soratto J, D. P. Carrying out a computer-aided thematic content analysis with ATLAS.ti MMG Working Paper."},{"issue":"7","key":"501_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health."},{"issue":"7624","key":"501_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"issue":"6","key":"501_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042.","journal-title":"Int J Qual Health Care"},{"key":"501_CR26","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","volume":"12","author":"T Wilke","year":"2018","unstructured":"Wilke T, Mueller S, Bauer S, Pitura S, Probst L, Ratsch BA, et al. Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Prefer Adherence. 2018;12:2387\u201396. https:\/\/doi.org\/10.2147\/PPA.S183187.","journal-title":"Patient Prefer Adherence."},{"issue":"2","key":"501_CR27","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.36834\/cmej.36848","volume":"9","author":"F Warde","year":"2018","unstructured":"Warde F, Papadakos J, Papadakos T, Rodin D, Salhia M, Giuliani M. Plain language communication as a priority competency for medical professionals in a globalized world. Can Med Educ J. 2018;9(2):e52\u20139.","journal-title":"Can Med Educ J."},{"issue":"5","key":"501_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.sapharm.2012.10.007","volume":"9","author":"MY Smith","year":"2013","unstructured":"Smith MY, Wallace LS. Reducing drug self-injection errors: a randomized trial comparing a \u201cstandard\u201d versus \u201cplain language\u201d version of Patient Instructions for Use. Res Social Adm Pharm. 2013;9(5):621\u20135. https:\/\/doi.org\/10.1016\/j.sapharm.2012.10.007.","journal-title":"Res Social Adm Pharm."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-021-00501-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00501-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T18:26:00Z","timestamp":1628706360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-021-00501-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1007\/s40271-021-00501-7","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"12 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen Global Services, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jianming He, Annette Lam, Katherine Gries, Robin Carson, and Nicola Trevor are employees of Janssen and own company stocks. Ashley Duenas, Hannah Collacott, and Tommi Tervonen are employees of Evidera, which received funding from Janssen for work related to this study. Dietrich Potthoff is an employee of Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available because no consent was sought from participants to allow sharing of data with third parties.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study protocol and the informed consent forms received ethical approval from a central institutional review board (Ethical and Independent Review Services, Independence, MO, USA).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed written consent prior to being interviewed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Jianming He, Ashley Duenas, Hannah Collacott, Annette Lam, Katherine Gries, Dietrich Potthoff, Nicola Trevor, and Tommi Tervonen were involved in the study conception and design. Ashley Duenas, Hannah Collacott, and Tommi Tervonen performed the formal data analysis. All authors were involved in the interpretation of data, contributed to the drafting of the manuscript, and approved the final version.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}